Why would that be? Can go both ways, either they're seeing that no big improvement going to two doses per week over a single shot (better for patients and access), or they're running into some sort of tox issues. Either way, how this hasnt been updated to the market is mind boggling. Seems patients in the trial have a nice inside rail on how the company is actually doing business versus what is out there on the market. Sorry - but from what i can see this (if true) is an absolute s**tshow. I'd like to know how much money has been spent on 008 so far just to see how much money has been flushed down the toilet. Add that to the NFL PR stunt. IMO
Sass, page-51
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.5¢ |
Change
0.010(3.64%) |
Mkt cap ! $99.69M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 28.5¢ | 27.5¢ | $8.001K | 28.94K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 45176 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.5¢ | 15217 | 5 |
View Market Depth
| Last trade - 10.50am 11/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |